GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 105 filers reported holding GENMARK DIAGNOSTICS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $595,277 | +32.6% | 24,907 | -19.0% | 0.01% | +50.0% |
| Q4 2020 | $449,038 | +2.8% | 30,756 | 0.0% | 0.00% | -20.0% |
| Q3 2020 | $436,735 | -3.5% | 30,756 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $452,421 | +316.7% | 30,756 | +16.7% | 0.01% | +150.0% |
| Q1 2020 | $108,562 | -14.3% | 26,350 | 0.0% | 0.00% | +100.0% |
| Q4 2019 | $126,744 | -20.6% | 26,350 | 0.0% | 0.00% | -50.0% |
| Q3 2019 | $159,681 | -6.6% | 26,350 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $171,012 | -8.5% | 26,350 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $186,822 | +45.9% | 26,350 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $128,061 | -33.9% | 26,350 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $193,673 | +15.3% | 26,350 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $168,000 | +17.5% | 26,350 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $143,000 | – | 26,350 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEEDHAM INVESTMENT MANAGEMENT LLC | 1,443,400 | $5,947,000 | 1.68% |
| Casdin Capital, LLC | 3,365,000 | $13,864,000 | 1.47% |
| Lyon Street Capital, LLC | 191,656 | $790,000 | 1.26% |
| CADIAN CAPITAL MANAGEMENT, LP | 3,489,055 | $14,375,000 | 0.71% |
| Portolan Capital Management | 893,090 | $3,680,000 | 0.55% |
| Eversept Partners, LP | 524,257 | $2,159,939 | 0.54% |
| Bullseye Asset Management LLC | 78,961 | $325,000 | 0.39% |
| Parkman Healthcare Partners LLC | 200,000 | $824,000 | 0.38% |
| Granite Investment Partners, LLC | 757,878 | $3,122,000 | 0.20% |
| Bellevue Group AG | 2,411,926 | $9,937,000 | 0.19% |